INVECTYS, INC. TO PARTICIPATE IN THE 41ST JP MORGAN HEA...
INVECTYS, INC. TO PARTICIPATE IN THE 41ST JP MORGAN HEALTHCARE CONFERENCE ON JANUARY 9-12, 2023 Houston, Texas, January 5, 2023 – Invectys, Inc. “Invectys”,…
Read more
INVECTYS, INC. TO PARTICIPATE IN THE 41ST JP MORGAN HEALTHCARE CONFERENCE ON JANUARY 9-12, 2023 Houston, Texas, January 5, 2023 – Invectys, Inc. “Invectys”,…
Invectys and CTMC Announce FDA Clearance of IND Application for Anti-HLA-G CAR-T Cell Therapy FDA granted IND clearance for IVS-3001, Invectys’s lead…
FRANÇOIS LESCURE, GENERAL MANAGER OF INVECTYS SAS, TO PARTICIPATE IN THE ABBVIE PARTNERING DAY IN PARIS, FRANCE ON OCTOBER 4TH, 2022 Paris, France, September…
Monoclonal antibodies targeting checkpoint inhibitors are hugely important immunotherapy molecules for the treatment cancers…
The telomerase enzyme functions as part of a large ensemble of proteins and RNA called the telomerase ribonucleoprotein complex.…
The main product of Invectys is a DNA vaccine targeting Telomerase…